Skip to main content

Table 1 Clinical characteristics of the study cohort

From: The NETest liquid biopsy is diagnostic for gastric neuroendocrine tumors: observations on the blood-based identification of microscopic and macroscopic residual disease

Variable Category GNET Type 1 GNEN G3 Controls
Number No. 42 4 63
Gender Males 10 3 20
Females 32 1 43
Age Mean (range) 55 (28–87) 55 (40–84) 44 (23–78)
Age at initial diagnosis Mean (range) 53 (27–81) 51 (38–83) N/A
Follow-up since initial diagnosis (years) Mean (range) 2.6 (0.12–14.7) 3.8 (0.5–10.5) N/A
Grade Grade 1 32 N/A
Grade 2 10
Grade 3 NET 1
NEC 3
Ki-67 (%) Mean (range) 2.5 (1–17) 51 (30–75) N/A
Active Chronic Atrophic Gastritis % (N) 81% (34) N/A N/A
Gastrin Levels [N ≤ 115 pg/ml] % Elevated 75%a 25%b N/A
Mean FC (range) 4.2 (0.12–13.3) 0.57 (0.1–1.04)
Mean Value (range) 483 (18–1525) 66 (12–120)
Intestinal Metaplasia No. 31 0 N/A
Proton pump inhibitor treatment % On treatment 7% 25%  
Chromogranin A [N < 100μg/l] % Elevated 44% 25% N/A
Mean (range) 142 (20–700) 203 (20–700)
Disease extent by imaging and histology Image-positive & R1 15 1 N/A
Image-negative & R0 18 3
Image-negative & R1 9
Current treatment Type No (Surveillance) No (Surveillance) N/A
Previous treatments None 0 1 N/A
Polypectomy 24 0
Partial gastrectomy 7 1
Total gastrectomy 3 2
  1. N: within normal range; No.: number of cases; N/A: Not applicable; FC: Fold change; a 2 subjects on PPI; b hypergastrinemia on PPI; R – resection/polypectomy margin; Chromogranin A assay: ELISA (Tecan Sunrise, Austria); Gastrin Levels [N ≤ 115 pg/ml]